Analysis of microarray-identified genes and MicroRNAs associated with Trifluridine resistance in colorectal cancer

Analysis of microarray-identified genes and MicroRNAs associated with Trifluridine resistance in colorectal cancer

Trifluridine (FTD) is an effective drug for advanced colorectal cancer (CRC); however, the molecular mechanisms underlying FTD resistance has not been elucidated. This study aimed to explore mRNAs and microRNAs (miRNAs) associated with FTD resistance in CRC. The analyzed data were downloaded from th...

Full description

Bibliographic Details
Main Authors:	Qiqi Zhang, Zhan Wang, Zhenghua Zhang, Lifei Zhu, Xijing Yang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	All Life
Subjects:	colorectal cancer trifluridine resistance degs mirna kegg pathways gene–drug interactions
Online Access:	http://dx.doi.org/10.1080/26895293.2022.2080280

Similar Items

Trifluridine–tipiracil plus bevacizumab versus trifluridine–tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024-06-01)

Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
by: Toshiaki Takahashi, et al.
Published: (2025-01-01)

Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
by: Celso Abdon Lopes de Mello, et al.
Published: (2022-12-01)

Long-Term Survival in a Patient with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil as Late-Line Chemotherapy: A Case Report
by: Bülent Karabulut, et al.
Published: (2024-06-01)

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
by: Long-Zhuan Huang, et al.
Published: (2024-11-01)

Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01)

PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
by: T. Sakakida, et al.
Published: (2024-09-01)

Eco-friendly HPTLC method for Trifluridine and Tipiracil determination: Quality-by-design meets green analytical chemistry
by: Amruta Balekundri, et al.
Published: (2025-06-01)

Identify CRNDE and LINC00152 as the key lncRNAs in age-related degeneration of articular cartilage through comprehensive and integrative analysis
by: Pengfei Hu, et al.
Published: (2019-05-01)

Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review
by: Taruba Rais, et al.
Published: (2024-07-01)

Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab
by: Masatsune Shibutani, et al.
Published: (2025-01-01)

Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study
by: Yukiya Narita, et al.
Published: (2024-06-01)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
by: Carlo Signorelli, et al.
Published: (2023-06-01)

Recent advances microRNAs and metabolic reprogramming in colorectal cancer research
by: Bin Xiong, et al.
Published: (2023-07-01)

Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer
by: Yoshitaka Saito, et al.
Published: (2024-11-01)

Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
by: Ruohong Lin, et al.
Published: (2024-12-01)

Skeletal Muscle Transcriptome Analysis of Hanzhong Ma Duck at Different Growth Stages Using RNA-Seq
by: Zhigang Hu, et al.
Published: (2021-02-01)

Applicable Pharmacokinetic Study: Development and Validation of Bioanalytical LC-MS/MS Method for Simultaneous Determination of Tipiracil, Trifluridine and Its Two Metabolites 5-Trifluoromethyluracil, 5-Carboxy 2′-Deoxyuridine in Rat Plasma
by: Manal El-Gendy, et al.
Published: (2023-12-01)

Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer
by: K. Fukuda, et al.
Published: (2024-03-01)

TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context
by: Lene Baeksgaard Jensen, et al.
Published: (2024-04-01)

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
by: Carlo Signorelli, et al.
Published: (2024-12-01)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
by: Naoki Takahashi, et al.
Published: (2023-08-01)

Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database
by: Yongli Hu, et al.
Published: (2024-07-01)

Identification of key biomarkers in breast cancer based on bioinformatics analysis and experimental verification
by: Yu Huan, et al.
Published: (2025-02-01)

Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice
by: M. Yu. Fedyanin
Published: (2020-12-01)

De novo Transcriptomic analysis to unveil the deltamethrin induced resistance mechanisms in Callosobruchus chinensis (L.)
by: Pankaj Sharma, et al.
Published: (2025-02-01)

Comparative Analysis of Hulless Barley Transcriptomes to Regulatory Effects of Phosphorous Deficiency
by: Likun An, et al.
Published: (2024-07-01)

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context
by: Niels A.D. Guchelaar, et al.
Published: (2025-02-01)

The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review
by: Athanasios Michas, et al.
Published: (2023-12-01)

TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
by: Ritam Joarder, et al.

Potential Diagnostic Utility of microRNAs in Gastrointestinal Cancers
by: Jelski W, et al.
Published: (2023-08-01)

Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization
by: Jason A. Hanna, et al.
Published: (2012-04-01)

MicroRNAs; their therapeutic and biomarker properties
by: Shahnam Azizi Dargahlou, et al.
Published: (2023-06-01)

MicroRNA expression profile in isolated circulating tumor cells in colorectal cancer
by: O. I. Kit, et al.
Published: (2023-04-01)

The Relationship Between Larynx Cancer and MicroRNAs
by: Murat Kaya, et al.
Published: (2020-09-01)

Clinical Implementation of MicroRNAs in Cancer Immunology
by: Heidi Schwarzenbach
Published: (2024-01-01)

LAT1 and ASCT2 Related microRNAs as Potential New Therapeutic Agents against Colorectal Cancer Progression
by: Francisca Dias, et al.
Published: (2021-02-01)

Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis
by: Maria Radanova, et al.
Published: (2022-01-01)

Identification of Upregulating Genes, Transcription Factors, and miRNAs in Vitiligo. In silico Study
by: AbdElneam AI, et al.
Published: (2024-09-01)

KEGGSum: Summarizing Genomic Pathways
by: Chaim David, et al.
Published: (2024-01-01)